Endocrinology

 
FreeStyle Libre 3 CGM Linked with Reduced Hospital Admissions in Patients with T2D
September 22, 2022

Hospital admissions among patients with T2D taking basal insulin only were reduced by 67% one year after beginning treatment with the CGM system.

Specific Blood Pressure Thresholds Not Needed When Selecting Patients with T2D for Antihypertensive Treatment, Suggests New Research
August 30, 2022

Blood pressure-lowering therapy reduced the risk of major CV events in persons with and without type 2 diabetes, according to an individual participant-level data meta-analysis.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes
July 22, 2022

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Patients with Diabetes Face Higher Risk for Left-sided Valvular Stenotic Lesions
June 14, 2022

A new study found patients with T1D and T2D had a greater risk for stenotic lesions, whereas risk for valvular regurgitation was lower in those with T2D.

Study: AI-powered Intervention Led to Highest Reported Rate of T2D Remission to Date
June 07, 2022

ADA 2022: Patients with T2D who received a treatment intervention powered by artificial intelligence achieved a remission rate of more than 80%.

Dulaglutide Improves HbA1c for Youth with Type 2 Diabetes without Change in BMI
June 07, 2022

ADA 2022: "Breakthrough" findings may help to address the unmet need for additional treatment options for young patients with type 2 diabetes.

Younger Age and Higher HbA1c Among Factors Linked to CGM Uptake in New Study
June 06, 2022

ADA 2022: Younger age, insulin use, higher HbA1c, and higher diabetes distress were found to be associated with CGM uptake in prospective study.

Patients with Diabetes Up to 4-times More Likely to Develop Long COVID-19
June 04, 2022

ADA 2022: In a new literature review, 43% of studies included identified diabetes as a potent risk for developing post-acute sequelae of COVID-19.

Tirzepatide Treatment Leads to Weight Loss of up to 22.5% in SURMOUNT-1 Clinical Trial
June 04, 2022

ADA 2022: Tirzepatide led overall to weight loss of up to 22.5% of baseline body weight with persons taking the 15 mg dose losing an average of 52 pounds.

Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
May 23, 2022

Compare, contrast, price shop, prescribe. DiabetesWise Pro developer Korey Hood, PhD, highlights the tool all primary care clinicians should try.